Sunday, 15 December 2013

Bristol, AstraZeneca withdraw diabetes drug in Germany

Bristol-Myers Squibb and AstraZeneca said they would pull a new diabetes drug from the German market because they had failed to agree on a price with a body of medical insurers. The decision to stop marketing oral drug dapagliflozin in Germany comes just a day after it was endorsed by an advisory panel to the U.S. Food and Drug Administration (Reuters)

No comments:

Post a Comment